Wed, 26th Apr 2023 07:38
(Sharecast News) - GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.
Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.
Reporting by Frank Prenesti for Sharecast.com
Sees $80 bln in 2030 revenue by 2030 *
(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatm...
(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating seve...
GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares ...
Haleon falls after GSK offloads remaining stake *
Glaxosmithkline (GSK)